





# EARLY AUTO TRANSPLANT FOR MYELOMA


Vikas Gupta, MD, PhD  
Assistant Professor




# PREVIOUS EVIDENCE FOR THE ROLE OF TRANSPLANT






Attal et. al. NEJM 1996





Child et. al. NEJM 2003



Palumbo et. al. NEJM 2014



Attal et. al. NEJM 2017



Cavo et. al. Lancet Hematology 2020



# THE CASE FOR EARLY AUTO



Copyright © 2000 David Farley, d-farley@metalab.unc.edu  
<http://metalab.unc.edu/Dave/drfun.html>

1

OS is not the right endpoint

2

The PFS benefit is important to patients

3


Transplant benefits high risk patients and is the best shot at a cure for standard risk

4

Delaying transplant risks no transplant

# OS IS NOT THE RIGHT ENDPOINT

- Overall survival was not the primary endpoint in DETERMINATION
- Median overall survival in our institutional experience with RVD and transplant is 10 years and **NR for SR patients (mFU 88m)**
- **Need longer follow up to see OS benefit**



Joseph et. al., JCO 2020





# PFS BENEFIT IS IMPORTANT TO PATIENTS

**Median PFS was 67.5 mo (ASCT) vs. 46.2 mo (RVD alone)**

**PFS and OS decrease with each subsequent line of therapy**

- PI and IMiD refractory OS = 13 months
- PI, IMiD, and MAb refractory OS = 9.2 months
- Penta-refractory OS = 5.6 months

**Improved tolerance and quality of life**





Richardson et. al., NEJM 2022

# BENEFITS OF TRANSPLANT

HDT-ASCT has repeatedly shown to lead to improved DOR and higher MRD negativity rates


- In DETERMINATION, MRD negativity **54%** vs **40%** favoring ASCT




Richardson et al, ASCO 2022; Joseph et. al., JCO 2020

# BENEFITS OF TRANSPLANT

**High risk: Significant PFS benefit**  
**55.5 months vs. 17.1 in RVD alone**



**Standard risk: Early transplant may be their best chance at cure**



Joseph, unpublished data,  
please do not post



## DELAYING TRANSPLANT RISKS NO TRANSPLANT

**Only 28% of patients in the RVD alone arm subsequently received transplant**

Richardson et al, ASCO 2022



# DELAYING TRANSPLANT RISKS HAVING TO LEARN A NEW EEMR

Dr. Kaufman

DR. KAUFMAN

Rosie



**EARLY AUTO IS SAFE,  
EFFECTIVE AND SHOULD  
REMAIN THE STANDARD OF  
CARE**

